Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Blood|April 6, 2001
ARG tyrosine kinase activity is inhibited by STI571K Okuda, E Weisberg, D G Gilliland, et al.
Cancer Genetics and Cytogenetics|October 25, 2001
The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivoP Andreasson, J Schwaller, E Anastasiadou, et al.
Leukemia Research|February 1, 1994
Clonality analysis of childhood ALL in remission: no evidence of clonal hematopoiesisL Busque, R Ilaria, R Tantravahi, et al.
Cell|April 22, 1994
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocationT R Golub, G F Barker, M Lovett, et al.
Oncogene|September 19, 1996
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell linesK Okuda, T R Golub, D G Gilliland, et al.
Blood|June 17, 1998
Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2)T S Ross, O A Bernard, R Berger, et al.
Cell|November 1, 1980
Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxicD B Cawley, H R Herschman, D G Gilliland, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 1978
Chimeric toxins: toxic, disulfide-linked conjugate of concanavalin A with fragment A from diphtheria toxinD G Gilliland, R J Collier, J M Moehring, et al.
Molecular and Cellular Biology|April 21, 2001
Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradationJ Frantsve, J Schwaller, D W Sternberg, et al.
Cancer|January 15, 1994
Bone marrow dysplasia in patients with newly diagnosed acute myelogenous leukemia does not correlate with history of myelodysplasia or with remission rate and survivalK K Ballen, D G Gilliland, L A Kalish, et al.
Pageof 9